The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial

被引:14
作者
Wang, Qiong [1 ,2 ,4 ]
Wang, Yi-Ru [1 ,2 ,4 ]
Jia, Qing-Yun [1 ,2 ,4 ]
Liu, Li [1 ,2 ,4 ]
Xu, Chong-Qing [1 ,2 ,4 ]
Wang, Xiao-Yun [1 ,2 ,4 ]
Yao, Min [1 ,2 ,4 ]
Cui, Xue-Jun [1 ,2 ,4 ]
Shi, Qi [1 ,2 ,4 ]
Wang, Yong-Jun [1 ,2 ,3 ,4 ]
Liang, Qian-Qian [1 ,2 ,4 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Orthopaed, 725 South Wan Ping Rd, Shanghai 200032, Peoples R China
[2] Shanghai Univ Tradit Chinese Med, Inst Spine, 725 South Wan Ping Rd, Shanghai 200032, Peoples R China
[3] Shanghai Univ Tradit Chinese Med, Rehabil Med Coll, 1200 Cai Lun Rd, Shanghai 201203, Peoples R China
[4] Shanghai Univ Tradit Chinese Med, Key Lab Theory & Therapy Muscles & Bones, Minist Educ, Shanghai, Peoples R China
关键词
Traditional Chinese medicine; Juanbi pill; Methotrexate; Active rheumatoid arthritis; Randomized controlled trial; HEALTH-ASSESSMENT QUESTIONNAIRE; DISEASE-ACTIVITY; 28-JOINT COUNTS; CLINICAL-TRIALS; VALIDATION; CRITERIA; EPIDEMIOLOGY; VARIABILITY; PERFORMANCE; IMPROVEMENT;
D O I
10.1186/s13063-018-2555-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by swelling and painful joints, eventually leading to joint destruction. There is still a lack of effective therapy to treat RA. The Juanbi pill is a Chinese medicine that has been widely used to treat active RA in China for hundreds of years, relieving pain and protecting the affected joints from malformation. However, there is no solid evidence to show the effect of the Juanbi pill on the management of active RA. Methods/design: We will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial to determine whether the traditional Chinese medicine Juanbi pill could relieve joint pain in RA and protect the joints. A total of 120 patients with active RA will be enrolled and treated with the Juanbi pill or a placebo for 3 months. The primary outcome measures are as follows: rate of in the American College of Rheumatology (ACR)50, change in the 28-joint Disease Activity Score (DAS28) from baseline at beginning of therapy to 3 months, and a change in the van der Heijde modified Sharp score measured from baseline to 12 months. The secondary outcome measures are as follows: rate of change in ACR20, ACR70, Health Assessment Questionnaire-Disability Index (HAQ-DI), and change in score in the Patient Assessment of Arthritis Pain, Patient Global Assessment of Arthritis, and the Athens Insomnia Scale (AIS) from baseline to 2-week, 1-month, 2-month, 3-month, 6-month, and 12-month follow up. In addition, the rate of change (score) in the ACR50 and DAS28 from the baseline to 2-week, 1-month, 2-month, 6-month, and 12-month follow up are also the secondary outcome measures. Discussion: Although the Juanbi pill has been used in China for many years to treat RA, there is a lack of consensus about its effectiveness. This trial will provide convincing evidence about the effect of Juanbi pill on active RA.
引用
收藏
页数:9
相关论文
共 34 条
[1]  
Bruce B, 2003, J RHEUMATOL, V30, P167
[2]  
Bruce B, 2005, CLIN EXP RHEUMATOL, V23, pS14
[3]   Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort [J].
Cader, Mohammed Z. ;
Filer, Andrew ;
Hazlehurst, Jonathan ;
de Pablo, Paola ;
Buckley, Christopher D. ;
Raza, Karim .
ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) :949-955
[4]   Mechanisms of disease: Cytokine pathways and joint inflammation in rheumatoid arthritis. [J].
Choy, EHS ;
Panayi, GS .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (12) :907-916
[5]   Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities [J].
Chung, C. P. ;
Thompson, J. L. ;
Koch, G. G. ;
Amara, I. ;
Strand, V. ;
Pincus, T. .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (12) :1602-1607
[7]   Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data [J].
Dougados, M. ;
Schmidely, N. ;
Le Bars, M. ;
Lafosse, C. ;
Schiff, M. ;
Smolen, J. S. ;
Aletaha, D. ;
van Riel, P. ;
Wells, G. .
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (04) :484-489
[8]   Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis [J].
Emery, Paul ;
Hammoudeh, Mohammed ;
FitzGerald, Oliver ;
Combe, Bernard ;
Martin-Mola, Emilio ;
Buch, Maya H. ;
Krogulec, Marek ;
Williams, Theresa ;
Gaylord, Stefanie ;
Pedersen, Ronald ;
Bukowski, Jack ;
Vlahos, Bonnie .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (19) :1781-1792
[9]  
FAYERS P, 1993, STAT MED, V12, P1643, DOI 10.1002/sim.4780121709
[10]   THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY CORE SET OF DISEASE-ACTIVITY MEASURES FOR RHEUMATOID-ARTHRITIS CLINICAL-TRIALS [J].
FELSON, DT ;
ANDERSON, JJ ;
BOERS, M ;
BOMBARDIER, C ;
CHERNOFF, M ;
FRIED, B ;
FURST, D ;
GOLDSMITH, C ;
KIESZAK, S ;
LIGHTFOOT, R ;
PAULUS, H ;
TUGWELL, P ;
WEINBLATT, M ;
WIDMARK, R ;
WILLIAMS, HJ ;
WOLFE, F .
ARTHRITIS AND RHEUMATISM, 1993, 36 (06) :729-740